EP4097120A4 - Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same - Google Patents

Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same Download PDF

Info

Publication number
EP4097120A4
EP4097120A4 EP20915510.0A EP20915510A EP4097120A4 EP 4097120 A4 EP4097120 A4 EP 4097120A4 EP 20915510 A EP20915510 A EP 20915510A EP 4097120 A4 EP4097120 A4 EP 4097120A4
Authority
EP
European Patent Office
Prior art keywords
making
methods
same
binding peptide
peptide conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20915510.0A
Other languages
German (de)
French (fr)
Other versions
EP4097120A1 (en
Inventor
Junge ZHANG
Liang Zeng Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mainline Biosciences Shanghai Co Ltd
Original Assignee
Mainline Biosciences Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/752,690 external-priority patent/US11123437B2/en
Application filed by Mainline Biosciences Shanghai Co Ltd filed Critical Mainline Biosciences Shanghai Co Ltd
Publication of EP4097120A1 publication Critical patent/EP4097120A1/en
Publication of EP4097120A4 publication Critical patent/EP4097120A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP20915510.0A 2020-01-26 2020-03-27 Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same Pending EP4097120A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/752,690 US11123437B2 (en) 2017-09-05 2020-01-26 Selective CXCR4 binding peptide conjugate and methods for making and using the same
PCT/US2020/025522 WO2021150258A1 (en) 2020-01-26 2020-03-27 Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same

Publications (2)

Publication Number Publication Date
EP4097120A1 EP4097120A1 (en) 2022-12-07
EP4097120A4 true EP4097120A4 (en) 2024-05-01

Family

ID=76992501

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20915510.0A Pending EP4097120A4 (en) 2020-01-26 2020-03-27 Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same

Country Status (4)

Country Link
EP (1) EP4097120A4 (en)
JP (1) JP2023516878A (en)
CN (1) CN115003684A (en)
WO (1) WO2021150258A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150689A1 (en) * 2007-05-30 2008-12-11 Eli Lilly And Company Cyclic peptide cxcr4 antagonists
WO2019050564A1 (en) * 2017-09-05 2019-03-14 Mainline Biosciences High affinity cxcr4 selective binding conjugate and method for using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5308829B2 (en) * 2006-02-27 2013-10-09 テクニッシュ ユニべルシタット ミュンヘン Cancer imaging and treatment
US8906355B2 (en) * 2009-10-29 2014-12-09 Lucia Irene Gonzalez Synthetic stereoisomer peptides in the retro-inverso and inverso configuration, and with cyclic and linear structure, their polymer conjugates, their encapsulation in polymer particles, and uses thereof
IT1397901B1 (en) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche CYCLIC PEPTIDES THAT BIND THE CXCR4 RECEPTOR AND THEIR USE IN MEDICAL AND DIAGNOSTIC FIELDS.
EP2658981B1 (en) * 2010-12-29 2016-09-28 F.Hoffmann-La Roche Ag Small molecule conjugates for intracellular delivery of nucleic acids
CN102626522B (en) * 2012-04-12 2014-09-10 韩彦江 Polypeptide radioactive diagnosis and treatment medicament based on chemotactic factor receptor CXCR4 polypeptide antagonist
JP6047231B2 (en) * 2012-06-06 2016-12-21 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ β-hairpin peptidomimetics
EP3152226B1 (en) * 2014-06-06 2019-05-29 Technische Universität München Modified cyclopentapeptides and uses thereof
JP7100639B2 (en) * 2016-09-06 2022-07-13 メインライン バイオサエンシズ CXCR4 antagonist and usage

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150689A1 (en) * 2007-05-30 2008-12-11 Eli Lilly And Company Cyclic peptide cxcr4 antagonists
WO2019050564A1 (en) * 2017-09-05 2019-03-14 Mainline Biosciences High affinity cxcr4 selective binding conjugate and method for using the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ÅBERG OLA ET AL: "18F-labelling of a cyclic pentapeptide inhibitor of the chemokine receptor CXCR4", JOURNAL OF FLUORINE CHEMISTRY, vol. 135, 28 November 2011 (2011-11-28), pages 200 - 206, XP028897524, ISSN: 0022-1139, DOI: 10.1016/J.JFLUCHEM.2011.11.003 *
JENS ATZRODT ET AL: "Deuterium- and Tritium-Labelled Compounds: Applications in the Life Sciences", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, VERLAG CHEMIE, HOBOKEN, USA, vol. 57, no. 7, 16 August 2017 (2017-08-16), pages 1758 - 1784, XP072090446, ISSN: 1433-7851, DOI: 10.1002/ANIE.201704146 *
JOSEPH LAU ET AL: "[ 68 Ga]Ga/[ 177 Lu]Lu-BL01, a Novel Theranostic Pair for Targeting C-X-C Chemokine Receptor 4", MOLECULAR PHARMACEUTICS, vol. 16, no. 11, 23 September 2019 (2019-09-23), US, pages 4688 - 4695, XP055748853, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.9b00808 *
See also references of WO2021150258A1 *

Also Published As

Publication number Publication date
WO2021150258A9 (en) 2021-11-11
WO2021150258A1 (en) 2021-07-29
JP2023516878A (en) 2023-04-21
EP4097120A1 (en) 2022-12-07
CN115003684A (en) 2022-09-02

Similar Documents

Publication Publication Date Title
EP3991754A4 (en) Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof
EP3679053A4 (en) High affinity cxcr4 selective binding conjugate and method for using the same
EP4159757A4 (en) Sars-cov-2 spike protein binding molecule and application thereof
WO2007106744A3 (en) Anti-5t4 antibodies and uses thereof
EP4025257A4 (en) Antibody-drug conjugate comprising antibody against human ror1, and use for the same
SI1546734T1 (en) N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
MX2022009302A (en) Il-7rî± binding compounds.
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2007009099A3 (en) Apparatus and methods for occluding a hollow anatomical structure
EP3735271A4 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
EP3868711A4 (en) Mfi structure molecular sieve rich in mesopore, preparation method therefor, and catalyst containing same and application thereof
EP4146271A4 (en) Proteins binding nkg2d, cd16 and clec12a
EP3932948A4 (en) Antibody binding human lag-3, and preparation method and use thereof
EP3928790A4 (en) Cd3 antigen binding fragment and application thereof
TWI340143B (en) Graft copolymer and method for preparing the same
EP3858866A4 (en) Glp1-fc fusion protein and conjugate thereof
EP3985392A4 (en) Conjugate for immunodetection based on lateral flow assay, and immunodetection method using same
EP3777894A4 (en) Brain-targeting, long-acting protein conjugate, preparation method therefor, and composition comprising same
SG11202111629QA (en) Self-assembling protein nanocage decorated with antibodies (sapna) and parts thereof
WO2022170008A3 (en) Anti-il1rap antibodies
EP3521300A4 (en) Cyclic peptide, affinity chromatography carrier, labeled antibody, antibody-drug conjugate, and pharmaceutical preparation
EP4097120A4 (en) Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same
IL287809A (en) Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same
EP3865515A4 (en) Solid-phase support including igg-binding peptide, and igg separation method
WO2007071347A3 (en) Selective marking of immunoglobulin glycans

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220714

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0007060000

Ipc: A61K0047640000

A4 Supplementary search report drawn up and despatched

Effective date: 20240405

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 7/50 20060101ALI20240328BHEP

Ipc: C07K 5/12 20060101ALI20240328BHEP

Ipc: C07K 7/06 20060101ALI20240328BHEP

Ipc: A61P 35/00 20060101ALI20240328BHEP

Ipc: C07B 59/00 20060101ALI20240328BHEP

Ipc: A61K 51/08 20060101ALI20240328BHEP

Ipc: A61K 47/64 20170101AFI20240328BHEP